Education Center

Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults

This supplement is sponsored by Salix Pharmaceuticals.

 

Click to read supplement.

In this supplement to Clinician Reviews , Christine Frissora, MD, provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined.

Topics include:

  • IBS-D diagnosis and treatment challenges
  • The role of microbial imbalance and altered gut microbiota
  • A treatment option for relief of IBS-D symptoms

Click to read supplement.

XIFI.0273.USA.18

Recommended Reading

Occult blood in feces linked to more than just colorectal cancer mortality
Clinician Reviews
Fecal transplantation suggests IBS efficacy in small, randomized studies
Clinician Reviews
Prolonged opioid use among U.S. IBD patients doubled during 2002-2016
Clinician Reviews
NAFLD less common, more severe in black children
Clinician Reviews
Children’s ‘gluten-free’ foods are no healthier than others
Clinician Reviews
Diverticulitis: A Primer for Primary Care Providers
Clinician Reviews
Psychological screening integration improves quality of care for children with abdominal pain
Clinician Reviews
Pediatric appendectomy fast track reduced LoS, narcotic use
Clinician Reviews
Genetic composition of HCV changes with HIV coinfection
Clinician Reviews
Immunosuppression often triggers skin side effects
Clinician Reviews